目的:分析布地奈德雾化吸入联合胸腺肽治疗哮喘-慢阻肺重叠综合征(Asthma COPD overlap syndrome,ACOS)的临床效果.方法:回顾性分析 2020 年 1 月至 2023 年 10 月期间本院呼吸内科收治的 75 例ACOS患者的临床资料.根据治疗方法的不同,患者分为对照组(采用胸腺肽治疗,n=38)和观察组(采用布地奈德雾化吸入联合胸腺肽治疗,n=37).治疗3 w后采用哮喘控制测试评分(Asthma Control Test,ACT)、慢阻肺自我评估测试问卷(COPD assessment test,CAT)评分评估患者症状改善情况;采用肺功能检测仪测定患者用力肺活量(Forced vital capacity,FVC)、第 1秒用力呼气量(Forced Expiratory Volume in one second,FEV1)水平;采用全自动生化分析仪测定患者血清C反应蛋白(C-reactive protein,CRP)、白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子(Tumour necrosis factor-α,TNF-α)水平;并统计不良反应发生情况.结果:与治疗前相比,两组ACT评分明显增加,CAT评分明显降低,其中观察组更为显著(P＜0.05).与治疗前相比,两组FVC、FEV1水平均明显提高,其中观察组更为显著(P＜0.05).与治疗前相比,两组CRP、IL-6、TNF-α水平均明显降低,其中观察组更为显著(P＜0.05).观察组不良反应发生率(21.62%)与对照组(18.42%)相比,差异无统计学意义(P＞0.05).结论:ACOS患者采用布地奈德雾化吸入联合胸腺肽治疗可改善临床症状及肺功能,降低炎症反应,且安全性较高.
Application of budesonide aerosol inhalation combined with thymosin in patients with asthma-COPD overlap syndrome
Objective:To analyze the clinical effect of budesonide aerosol inhalation combined with thymosin in the treatment of asthma-COPD overlap syndrome(Asthma COPD overlap syndrome,ACOS).Methods:Retrospective analysis of clinical data of 75 ACOS patients admitted to the Department of Respiratory Medicine in our hospital from January 2020 to October 2023.According to different treatment methods,patients were divided into a control group(treated with thymosin,n=38)and an observation group(treated with budesonide nebulization combined with thymosin,n=37).After 3 weeks of treatment,the asthma control test score(ACT),COPD assessment test(CAT)score were used to evaluate the improvement of patient symptoms.The forced vital capacity(FVC),forced expiratory volume in one second(FEV1)levels were measured using a pulmonary function detector;the serum C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)levels were measured using a fully automatic biochemical analyzer.Also,the incidence of adverse reactions was statistically analyzed.Results:Compared with before treatment,the ACT scores of both groups increased significantly,while the CAT scores decreased significantly,with the observation group being more significant(P<0.05).Compared with before treatment,the levels of FVC and FEV1 in both groups increased significantly,with the observation group being more significant(P<0.05).Compared with before treatment,the levels of CRP,IL-6,and TNF-α in both groups decreased significantly,with the observation group being more significant(P<0.05).The incidence of adverse reactions in the observation group(21.62%)was not significantly different from that in the control group(18.42%)(P>0.05).Conclusion:The treatment of ACOS patients with budesonide nebulization combined with thymosin can improve clinical symptoms and lung function,reduce inflammatory response,and has high safety.
NETL
NSTL
万方数据
